← Russell 3000 cross-section

IQV IQVIA HOLDINGS INC.

Trailing twelve months to 2026-03-31 · as filed 2026-05-05, not restated
Healthcare

Scale

Market cap
$43.5bn
Revenue TTM
$16.6bn
Net income TTM
$1.4bn
Free cash flow
$2.1bn
Composite score
52.4
Sector rank
#265

Valuation

P / E
31.4
EV / EBITDA
16.4
EV / sales
3.3
FCF yield
4.87%
Earnings yield vs 10-yr
-1.54pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
8.3%
EBITDA margin
20.2%
ROE
22.3%
ROIC
12.2%
Revenue growth
7.3%

Insider activity, last 90 days

Net open-market
$-29.19m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We were previously managed through three reportable segments, Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. As a result, the Contract Sales & Medical Solutions segment, which had become more closely related operationally to the Technology & Analytics Solutions segment commercial offerings, was incorporated into the Technology & Analytics Solutions segment, which was renamed Commercial Solutions. Revenues For the second quarter of 2026, our revenues increased $351 million, or 8.7%, as compared to the same period in 2025. …IQVIA HOLDINGS INC., 10-Q, period ended 2026-06-30, filed 2026-07-28

Read the full passage →